<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998023</url>
  </required_header>
  <id_info>
    <org_study_id>479-2009</org_study_id>
    <nct_id>NCT00998023</nct_id>
  </id_info>
  <brief_title>Patient Comfort With Vascular Closure</brief_title>
  <official_title>Patient Comfort Study With Vascular Closure: Mynx vs. Angio-Seal Evolution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Access Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to collect information on the amount of discomfort
      patients experience with one of two different vascular blood vessel closure devices, the
      MynxM5 Vascular Closure Device and the Angio-Seal Evolution Vascular Closure Device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The traditional, standard technique of achieving femoral artery hemostasis following
      diagnostic and interventional catheterization procedures requires compression methods such as
      manual pressure or clamps held at the puncture site for 10 to 30 minutes, or even longer
      depending on sheath size and anticoagulation status. This traditional method can be
      associated with patient discomfort as well as prolonged bed rest, ambulation and hospital
      discharge.

      Over the past decade, Vascular Closure Devices (VCDs), which include collagen hemostasis
      devices, percutaneous suture-mediated closure devices and metallic clips, have emerged as a
      novel means for reducing time to hemostasis and ambulation following catheterization
      procedures performed utilizing femoral arterial access. Previous studies with commercially
      available VCDs have shown that the reduction in time to hemostasis and time to ambulation and
      discharge have also led to increased patient satisfaction over manual compression.

      The MynxM5 Vascular Closure Device received FDA approval on April 8, 2009. Like the Mynx 6/7F
      Vascular Closure Device, which received FDA approval on May 16, 2007, both are designed to
      achieve femoral artery hemostasis via delivery of an extravascular, water-soluble synthetic
      sealant which expands upon contact with subcutaneous fluids to seal the arteriotomy. In
      theory, the lack of pressure needed to clamp, suture, clip or cinch, which is required with
      intravascular closure devices, may provide an advantage in regards to increased patient
      comfort during closure device deployment when using the Mynx.

      Although VCDs have demonstrated an increase in patient comfort and satisfaction over manual
      compression, little data exists regarding patient comfort when comparing different closure
      devices. This study is designed to evaluate patient comfort between the MynxM5 and Angio-Seal
      Evolution Vascular Closure Devices.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Score on the Visual Analogue Scale</measure>
    <time_frame>Immediately before vascular closure and immediately after vascular closure.</time_frame>
    <description>The Visual Analogue Scale measures the severity of pain on a continuous scale from 0 (no pain) to 10 (worst possible pain).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Complications</measure>
    <time_frame>1 Day</time_frame>
    <description>Number of participants with permanent access site-related nerve injury, access-site related surgical/vascular repair, amputation related to access closure complication, access site-related bleeding/hematoma requiring transfusion, any new ipsilateral lower extremity ischemia requiring non-surgical intervention, local access site-related or generalized infection requiring prolonged hospitalization or re-hospitalization and treatment with IV antibiotics or inflammatory reaction that may include local signs and drainage, treated with re-hospitalization, IV antibiotics and/or surgical intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Vascular Closure</condition>
  <arm_group>
    <arm_group_label>Mynx VCD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mynx Vascular Closure Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AngioSeal VCD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AngioSeal Vascular Closure Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mynx Vascular Closure Device</intervention_name>
    <description>Comparison of two different vascular closure devices.</description>
    <arm_group_label>Mynx VCD</arm_group_label>
    <other_name>Mynx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AngioSeal Vascular Closure Device</intervention_name>
    <description>Comparison of two different vascular closure devices.</description>
    <arm_group_label>AngioSeal VCD</arm_group_label>
    <other_name>AngioSeal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is &gt;18 years of age

          -  Patient has been informed and understands the nature of the study and provides written
             Informed Consent approved by the appropriate Institutional Review Board prior to
             enrollment

          -  Patient has been trained and understands the use of the 0-10 Visual Analogue Scale as
             an assessment of patient pain

          -  Patient is scheduled to undergo a diagnostic endovascular procedure involving
             percutaneous access through the common femoral artery

        Exclusion Criteria:

          -  Per Mynx and Angio-Seal Instructions for Use

          -  Patient has a documented psychiatric disorder (e.g. major depression, anxiety)

          -  Patient has a documented chronic pain condition requiring daily treatment

          -  Patient carries the diagnoses of a known bleeding disorder

          -  Intraprocedural Exclusion Criteria: Patient has a baseline ipsilateral groin pain
             rating of &gt;1 on the 0-10 Visual Analog Scale prior to closure device deployment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Mocco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2009</study_first_submitted>
  <study_first_submitted_qc>October 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2009</study_first_posted>
  <results_first_submitted>September 21, 2011</results_first_submitted>
  <results_first_submitted_qc>December 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2011</results_first_posted>
  <last_update_submitted>December 5, 2011</last_update_submitted>
  <last_update_submitted_qc>December 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angiogram</keyword>
  <keyword>Catheter Angiogram</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the clinical practice of the investigator between November 2009 and July 2010.</recruitment_details>
      <pre_assignment_details>Participants who had any groin pain before placement of the closure device were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mynx VCD</title>
          <description>Mynx Vascular Closure Device</description>
        </group>
        <group group_id="P2">
          <title>AngioSeal VCD</title>
          <description>AngioSeal Vascular Closure Device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mynx VCD</title>
          <description>Mynx Vascular Closure Device</description>
        </group>
        <group group_id="B2">
          <title>AngioSeal VCD</title>
          <description>AngioSeal Vascular Closure Device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Score on the Visual Analogue Scale</title>
        <description>The Visual Analogue Scale measures the severity of pain on a continuous scale from 0 (no pain) to 10 (worst possible pain).</description>
        <time_frame>Immediately before vascular closure and immediately after vascular closure.</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Mynx VCD</title>
            <description>Mynx Vascular Closure Device</description>
          </group>
          <group group_id="O2">
            <title>AngioSeal VCD</title>
            <description>AngioSeal Vascular Closure Device</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Score on the Visual Analogue Scale</title>
          <description>The Visual Analogue Scale measures the severity of pain on a continuous scale from 0 (no pain) to 10 (worst possible pain).</description>
          <population>Per protocol</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Closure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="1.01"/>
                    <measurement group_id="O2" value="0.59" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After Closure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="0.42"/>
                    <measurement group_id="O2" value="5.03" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Complications</title>
        <description>Number of participants with permanent access site-related nerve injury, access-site related surgical/vascular repair, amputation related to access closure complication, access site-related bleeding/hematoma requiring transfusion, any new ipsilateral lower extremity ischemia requiring non-surgical intervention, local access site-related or generalized infection requiring prolonged hospitalization or re-hospitalization and treatment with IV antibiotics or inflammatory reaction that may include local signs and drainage, treated with re-hospitalization, IV antibiotics and/or surgical intervention</description>
        <time_frame>1 Day</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Mynx VCD</title>
            <description>Mynx Vascular Closure Device</description>
          </group>
          <group group_id="O2">
            <title>AngioSeal VCD</title>
            <description>AngioSeal Vascular Closure Device</description>
          </group>
        </group_list>
        <measure>
          <title>Major Complications</title>
          <description>Number of participants with permanent access site-related nerve injury, access-site related surgical/vascular repair, amputation related to access closure complication, access site-related bleeding/hematoma requiring transfusion, any new ipsilateral lower extremity ischemia requiring non-surgical intervention, local access site-related or generalized infection requiring prolonged hospitalization or re-hospitalization and treatment with IV antibiotics or inflammatory reaction that may include local signs and drainage, treated with re-hospitalization, IV antibiotics and/or surgical intervention</description>
          <population>Per protocol</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mynx VCD</title>
          <description>Mynx Vascular Closure Device</description>
        </group>
        <group group_id="E2">
          <title>AngioSeal VCD</title>
          <description>AngioSeal Vascular Closure Device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The Angio-Seal Evolution is only one of a variety of potential vascular closure devices available on the market that would be suitable for comparison with the Mynx; however, this study was limited to just one of such alternative devices.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>J Mocco, M.D.</name_or_title>
      <organization>University of Florida</organization>
      <phone>352-273-9000</phone>
      <email>jmocco@neurosurgery.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

